As­traZeneca’s Truqap com­bo flops in Phase 3 triple-neg­a­tive breast can­cer tri­al

As­traZeneca’s Truqap failed to boost sur­vival in a late-stage test in cer­tain pa­tients with triple-neg­a­tive breast can­cer, deal­ing a blow to the com­pa­ny’s ef­forts to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.